The stock currently trades at an attractive valuation of 1.1x Sep'24E ABV. We maintain our target multiple of 1.5x Sep'24E ABV to arrive at a target price of Rs 170/share, implying an upside of 32% from the CMP. We reiterate our BUY recommendation on the stock.